Related Experiment Video

Updated: May 28, 2026

Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting
07:36

Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting

Published on: May 1, 2015

The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma

Elisa Oricchio1, Gouri Nanjangud, Andrew L Wolfe

  • 1Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

Cell
|November 1, 2011
PubMed

Insights

The ephrin receptor A7 (EPHA7) acts as a tumor suppressor in follicular lymphoma (FL). A variant, EPHA7(TR), shows therapeutic potential by blocking cancer signals and reducing tumor growth.

Area of Science:

  • Oncology
  • Cancer Genetics
  • Molecular Biology

Background:

  • Follicular lymphoma (FL) genetics offer therapeutic targets.
  • Identifying novel tumor suppressors is crucial for FL treatment.

Purpose of the Study:

  • To identify novel tumor suppressors in follicular lymphoma.
  • To explore the therapeutic potential of the ephrin receptor A7 (EPHA7) in FL.

Main Methods:

  • Cross-referencing chromosomal changes with genetic screens.
  • Utilizing a murine FL model to assess EPHA7 function.
  • Investigating a soluble splice variant of EPHA7 (EPHA7(TR)) for its anti-cancer activity.

Main Results:

  • EPHA7 identified as a tumor suppressor, targeted by 6q deletions and inactivated in 72% of FLs.
  • EPHA7 knockdown accelerates lymphoma development in a murine model.
  • EPHA7(TR) blocks oncogenic signals and exhibits antitumor effects in xenograft models.
  • Fusion of EPHA7(TR) to rituximab enables targeted delivery to lymphomas.

Conclusions:

  • EPHA7 is a critical tumor suppressor in follicular lymphoma.
  • The soluble EPHA7(TR) variant demonstrates significant therapeutic potential.
  • Combining genomics with functional screens is a powerful approach for discovering cancer therapeutics.

More Related Videos

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Related Concept Videos

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...